Morphine News and Research

Latest Morphine News and Research

New preclinical approach can guide more efficient drug development for brain-related conditions

The development of drugs for brain-related conditions is not an efficient process; only 8% of candidate drugs that enter clinical trials gain FDA approval. A key reason for this low success rate is a lack of preclinical tests that accurately predict drug efficacy and detect unwanted side effects.

9 Aug 2011

AstraZeneca recruits patients for KODIAC Phase III trial in opioid-induced constipation

AstraZeneca today announced that study centers across the U.S. are recruiting patients for a clinical study to examine whether an investigational drug is safe and effective in treating opioid-induced constipation.

2 Aug 2011

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

Covidien, a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) recently granted approval to the company's Mallinckrodt business for morphine sulfate oral solution, used to relieve moderate to severe acute and chronic pain in opioid-tolerant patients. The solution will be available as a generic in 100 milligrams per 5 mL (20 milligrams per 1 mL).

1 Aug 2011

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

BioDelivery Sciences International, Inc. announced today that the last patient has completed the randomized portion of its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain, signifying completion of the trial.

25 Jul 2011

Study finds high prevalence of prescription pain medication addiction in chronic patients

A new study by Geisinger Health System researchers finds a high prevalence of prescription pain medication addiction among chronic pain patients.

22 Jul 2011

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA and ACTIQ.

22 Jul 2011

Dealing with chronic pain

For people with severe chronic pain like Kelly Young and Teresa Shaffer—both of whom have become patient advocates —coping with agony is a fact of life. Young suffers from rheumatoid arthritis while Shaffer's pain is linked primarily to another degenerative bone disease.

21 Jul 2011

Novel vaccine for treating heroin addiction

Researchers at The Scripps Research Institute have developed a highly successful vaccine against a heroin high and have proven its therapeutic potential in animal models.

21 Jul 2011

QRxPharma seeks NDA approval for MoxDuo IR

QRxPharma Limited announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US.

18 Jul 2011

Poisonous shrub extract may act as natural painkiller

An extract of the poisonous shrub Jatropha curcas acts as a strong painkiller and may have a mode of action different from conventional analgesics, such as morphine and other pharmaceuticals.

12 Jul 2011

Bio-Nucleonics' generic Metastron, an option for metastatic cancer bone pain therapy

Bio-Nucleonics' lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.

28 Jun 2011

FDA approves Lannett's NDA for Morphine Sulfate Oral Solution

Lannett Company, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the company's 505(b)(2) New Drug Application (NDA) for Morphine Sulfate Oral Solution on June 23, 2011.

24 Jun 2011

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

Endo Pharmaceuticals announced today that it received notification from the U.S. Food and Drug Administration (FDA) that Endo's complete response to the FDA's Jan. 7, 2011 Action Letter relating to Endo's new drug application (NDA) for a new formulation of OPANA ER has been accepted.

24 Jun 2011

SNP identification may help predict patients’ susceptibility to postoperative nausea and vomiting

There are several anesthetic complications that may have a hereditary background, including postoperative nausea and vomiting (PONV). Past observations have shown PONV to occur in blood relatives as far back as two to three generations.

23 Jun 2011

Risky behavior, psychiatric disorders and substance abuse contribute to opioid overdose

Deaths related to prescription opioid therapy are under intense scrutiny, prompting those in pain medicine-clinicians, patient advocates, and regulators-to understand the causes behind avoidable mortality in legitimately treated patients.

13 Jun 2011

Bio-Nucleonics resumes production of metastatic cancer drug, Strontium-89

Bio-Nucleonics, Inc., a life sciences Company, specializing in the development and manufacture of radiopharmaceuticals, medical devices and imaging agents, will be attending the Society of Nuclear Medicine (SNM) Annual Meeting, held in San Antonio, TX, June 4th through 8th, 2011.

8 Jun 2011

FDA issues revised PDUFA date for Lannett's Morphine Sulfate Oral Solution NDA

Lannett Company, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a revised Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2011 for the company's 505(b)(2) New Drug Application for Morphine Sulfate Oral Solution

7 Jun 2011

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Adolor Corporation today announced that it has completed enrollment in its Phase 2 clinical evaluation of ADL5945 in chronic, non-cancer pain patients with opioid-induced constipation (OIC).

6 Jun 2011

Research provides new understanding of how heroin affects the brain

New research from the Norwegian Institute of Public Health suggests that our understanding of how heroin affects the brain should be changed. A new report shows that heroin is metabolised to 6-MAM which then crosses the blood-brain barrier to cause the intoxicating effects that arise shortly after heroin administration.

27 May 2011

Novel compound could become an effective alternative to common narcotic analgesics

Scientists from the Florida campus of The Scripps Research Institute have for the first time accomplished a laboratory synthesis of a rare natural product isolated from the bark of a plant widely employed in traditional medicine.

23 May 2011

Morphine News and Research

Latest Morphine News and Research

New preclinical approach can guide more efficient drug development for brain-related conditions

AstraZeneca recruits patients for KODIAC Phase III trial in opioid-induced constipation

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

Study finds high prevalence of prescription pain medication addiction in chronic patients

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Dealing with chronic pain

Novel vaccine for treating heroin addiction

QRxPharma seeks NDA approval for MoxDuo IR

Poisonous shrub extract may act as natural painkiller

Bio-Nucleonics' generic Metastron, an option for metastatic cancer bone pain therapy

FDA approves Lannett's NDA for Morphine Sulfate Oral Solution

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

SNP identification may help predict patients’ susceptibility to postoperative nausea and vomiting

Risky behavior, psychiatric disorders and substance abuse contribute to opioid overdose

Bio-Nucleonics resumes production of metastatic cancer drug, Strontium-89

FDA issues revised PDUFA date for Lannett's Morphine Sulfate Oral Solution NDA

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Research provides new understanding of how heroin affects the brain

Novel compound could become an effective alternative to common narcotic analgesics

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Morphine News and Research

Latest Morphine News and Research

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in